Digital twin technology in bioprocessing: simulation and optimisation of pharmaceutical production

The growing complexity of bioprocesses in the pharmaceutical industry, particularly in the development of innovative

Optimisation of processes in the synthesis of oligonucleotides

Solid-phase oligonucleotide synthesis (SPOS) is a highly efficient and reproducible process, but it has significant

World Book Day: three essential reads for gaining a deeper understanding of RNA and therapeutic oligonucleotides

Every 23 April, World Book Day invites us to reflect on the value of knowledge

The SYOLIGO project at major international oligonucleotide and RNA forums

Sylentis, a PharmaMar Group company, obtains Good Manufacturing Practice certification from the European Medicines Agency for its new industrial plant

This recognition from the European Medicines Agency (EMA) is one of the most demanding regulatory

Sylentis, compañía del Grupo PharmaMar, obtiene la certificación de Normas de Correcta Fabricación de la Agencia Europea de Medicamentos para su nueva planta industrial

Este reconocimiento de la Agencia Europea de Medicamentos (EMA) es una de las certificaciones reglamentarias

2025: a decisive year for SYOLIGO on its third anniversary

The year 2025 has marked a very special milestone for Sylentis and the SYOLIGO project:

siRNAs: advances, challenges and opportunities for European biotechnology

The recent article “Recent Update on siRNA Therapeutics” from the International Journal of Molecular Sciences

IPCEI Health MED4CURE: the project Syoligo by Sylentis, example of biomedical innovation with an impact on health and employment

On 15 December 2025, the CDTI hosted the IPCEI Health MED4CURE conference in Madrid, a

Towards personalized RNA medicine in cardiovascular diseases

Cardiovascular diseases (CVD) remain the leading cause of death worldwide. Despite advances in conventional medicine,

Sylentis strengthens its role as a leader in RNA biotechnology and oligonucleotide manufacturing

In October 2025, Sylentis participated in the annual conference of the Oligonucleotide Therapeutics Society (OTS)

Sylentis strengthens its position in RNA biotechnology and consolidates its position as a pioneering CDMO in therapeutic oligonucleotides

Interview with Ana Isabel Jiménez, Managing Director of Sylentis, on the occasion of OTS Budapest

Analytical methods in the manufacture of therapeutic oligonucleotides: ensuring quality and sustainability

The manufacture of therapeutic oligonucleotides is advancing, driven by the ability of these molecules to

Sylentis drives the debate on innovation and sustainability at Farmaforum 2025 by presenting the innovations of the SYOLIGO (IPCEI) project

The latest edition of Farmaforum 2025, held in Madrid, once again brought together the main

The strategic role of CDMOs in the development of oligonucleotide-based therapies

The advancement of oligonucleotide-based therapies has marked a turning point in modern medicine. In this

Circular RNA: broadening horizons in RNA-based therapies

In recent years, RNA-based therapies have gained prominence, with six recent marketing approvals between 2023

The Ministry of Science, Innovation and Universities grants 127 million euros to Spanish companies to promote research in the field of health and pharmaceutical production.

The beneficiary companies participate in the Major Project of Common European Interest in Health (IPCEI)

How is the first dose determined in humans for oligonucleotide therapies?

Oligonucleotide-based treatments capable of silencing specific genes have made it possible to tackle previously untreatable

AI-Assisted Drug Design: Realities, Challenges and Future Prospects

For decades, the search for and optimisation of new therapeutic agents has been an arduous,

Antisense oligos for the treatment of eye diseases

Antisense oligonucleotides (ASOs) are small synthetic nucleic acid sequences that have the potential to transform

21.1 million euro grant awarded to SYOLIGO project by CDTI under the Recovery, Transformation and Resilience Plan

CDTI has just published the proposed provisional resolution of the call for aid for direct

Sylentis, a PharmaMar Group company, will receive €21.1 million from the NextGenerationEU fund for research into rare diseases and the construction of a manufacturing plant

Sylentis, a PharmaMar Group (MSE:PHM) company, announces that the European Commission has today made public

Sylentis participates in the First General Assembly and Annual Conference of IPCEI Med4Cure in Paris

The city of Paris hosted the First General Assembly and Annual Conference of IPCEI Med4Cure,

Commission approves up to EUR 1 billion in state aid from seven Member States for the fourth major project of common European interest in the health sector

Brussels, May 28, 2024 The European Commission has approved, under EU state aid rules, a